Treatment of Cerebral Edema in Community-Acquired Bacterial Meningitis
Clinical Scenario
Patients with community-acquired bacterial meningitis are at significant risk for cerebral edema and its downstream neurological consequences. Timely, evidence-based intervention in this setting is critical to preserving function and reducing lasting harm.
Treatment Approach
Management centres on adjunctive intravenous corticosteroid therapy, coordinated with the timing of antibiotic initiation. The protocol specifies the agent, dosing schedule, duration, and weight-based adjustments — all of which are detailed in the full structured regimen.
Full dosing, timing requirements, and individual patient considerations are available in the complete protocol below.
Clinical Goal
The primary aim of this intervention is:
Reduction of neurological sequelae, primarily hearing loss
References
DOI: 10.1007/s12028-020-00959-7
- We recommend dexamethasone 10 mg intravenous every 6 h for 4 days to reduce neurological sequelae (primarily hearing loss) in patients with community-acquired bacterial meningitis (strong recommendation, moderate-quality evidence).
- We suggest dexamethasone 0.15 mg/kg intravenous every 6 h for 4 days as an alternative dose for patients with low body weight or high risk of corticosteroid adverse effects (good practice statement).
- We recommend administering dexamethasone before or with the first dose of antibiotic in patients with bacterial meningitis (strong recommendation, moderate-quality evidence).
View source ↗